The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia.
[clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP3 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP7 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased cleavage of CASP3 protein]; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein]; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein]
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP3 protein; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP3 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased cleavage of CASP3 protein]; [clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] results in increased cleavage of and results in increased activity of CASP3 protein; [resveratrol co-treated with clofarabine] results in increased expression of CASP3 protein modified form; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] results in increased activity of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein]
[clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP7 protein]; [clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in increased activity of CASP7 protein; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] results in increased activity of CASP7 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of CDKN1A protein]; [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of CDKN1A protein; [resveratrol co-treated with clofarabine] results in decreased expression of CDKN1A protein
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK2 protein; [clofarabine co-treated with fludarabine] results in increased phosphorylation of CHEK2 protein
[clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [resveratrol co-treated with clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein]; clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein]; resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein]
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; [resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein; [resveratrol co-treated with clofarabine] results in increased expression of PARP1 protein modified form; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein]
[resveratrol co-treated with clofarabine] affects the localization of SP1 protein; [resveratrol co-treated with clofarabine] results in decreased expression of SP1 protein
[resveratrol co-treated with clofarabine] affects the localization of TP53 protein modified form; [resveratrol co-treated with clofarabine] results in increased expression of and results in increased activity of TP53 protein modified form; TP53 protein affects the susceptibility to [resveratrol co-treated with clofarabine] Clofarabine affects the activity of TP53 protein
browse the term
